https://www.selleckchem.com/products/ABT-869.html
The safety end point of all-cause death will be updated semiannually and continued until the median duration of follow-up surpasses 5 years. Sub-group analyses will be conducted by device type, patient characteristics, and procedural setting. Registration The SAFE-PAD study has been registered on URL https//www.clinicaltrials.gov; Unique identifier NCT04496544. The SAFE-PAD study will evaluate the long-term safety of drug-coated devices compared with nondrug-coated devices for femoropopliteal artery revascularization among a broad, real
Aimer
Commentaire
Partagez
